Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. (NYSE: HIMS) is a health and wellness platform that regularly issues news about its digital care offerings, new specialties, and international growth. Company press releases highlight how the Hims and Hers brands use technology to connect customers with personalized care, with updates that span weight management, women’s health, labs and diagnostics, and broader platform developments.
Recent news has focused heavily on weight loss and metabolic health. Hims & Hers has launched a comprehensive Weight Loss Programme in the UK, including the official introduction of the Hers platform there, giving eligible women access to doctor-designed GLP‑1 treatment plans and holistic support for nutrition, movement, and sleep. In Canada, the company is entering the market through the acquisition of Livewell, a digital health platform focused on weight loss treatment, with plans to roll out an accessible, comprehensive weight loss program for Canadian customers.
Another key news theme is women’s health. The Hers platform has introduced a menopause and perimenopause specialty that offers eligible women access to treatment plans tailored to their health history and preferences, including prescription options such as estradiol and progesterone when deemed appropriate by licensed providers. News coverage also includes the launch of Labs, a testing experience that measures biomarkers across areas like heart health, metabolism, hormones, inflammation, and stress, pairing results with doctor-developed action plans.
Investors and followers of HIMS news will also see announcements about strategic acquisitions, such as the definitive agreement to acquire YourBio Health and its virtually painless TAP blood sampling technology, as well as corporate updates like share repurchase authorizations, financial results, leadership appointments, and facility investments. This news page aggregates these developments so readers can monitor how Hims & Hers is expanding its digital health platform, adding new capabilities, and executing its strategy across the United States, Europe, and Canada.
Hims & Hers reported Q1 2022 revenue of $101.3 million, a 94% increase year-over-year, surpassing the $100 million mark for the first time. The company also achieved a net loss of $(16.3) million, improved from $(51.4) million in Q1 2021. Member subscriptions grew by 101,000 to 710,000, an 82% increase. The company raised its full year 2022 revenue guidance to between $410 million and $425 million, while maintaining Adjusted EBITDA guidance of $(30 million) to $(20 million).
Hims & Hers Health, Inc. (NYSE: HIMS) will report its Q1 2022 financial results on May 9, 2022, at 4:15 p.m. E.T., followed by a conference call at 5:00 p.m. E.T. Participants can dial +1 (888) 510-2630 for U.S. access or +1 (646) 960-0137 for international access, using conference ID #1704296. A live audio webcast will be available at investors.forhims.com, with a replay accessible for 12 months.
Hims & Hers is a telehealth platform offering diverse healthcare services and can be accessed via a mobile app and retail locations across the U.S. and the U.K.
Hims & Hers has formed a partnership with Carbon Health to enhance its telehealth platform, now active in seven U.S. states. This collaboration aims to provide patients with broader access to personalized healthcare for complex conditions. Licensed professionals on the Hims & Hers platform will refer patients needing comprehensive care to Carbon Health. This partnership reflects Hims & Hers' strategy to improve healthcare delivery and patient outcomes by combining digital and in-person services, ultimately creating a more integrated healthcare system.
Hims & Hers Health, Inc. (NYSE: HIMS) has expanded its skincare collection, introducing new products aimed at addressing various skincare concerns. The lineup includes a facial cleanser, moisturizer, daily SPF, spot corrector, and face oil, formulated to avoid irritants and unnecessary fragrances. Co-founder Hilary Coles emphasized the brand's focus on personalized skincare experiences. The new products are now available at select CVS Pharmacy locations and through the company's websites, aiming to enhance consumer accessibility to effective skincare options.
Hims & Hers Health, Inc. (NYSE: HIMS) announced a partnership with Goodpath to enhance its mobile app offering. This collaboration will provide Hims & Hers members access to curated educational content regarding sleep, musculoskeletal issues, back pain, and gastroesophageal reflux disease (GERD). The app will feature programming tailored by medical advisors to better support users facing these health concerns. With a focus on personalized health and wellness experiences, this initiative aims to further improve the quality of care for the 500,000 subscription members.
Hims & Hers Health has appointed Amee Parekh as the new Senior Vice President of Human Resources. With a strong background in scaling high-growth companies, including her previous role at Uber, Parekh is set to enhance Hims & Hers' rapid growth trajectory. The company reported an impressive revenue increase of 83% year-over-year in 2021, totaling $271.9 million, alongside a 95% growth in member subscriptions in Q4 2021. This hire comes amid a series of leadership changes aimed at fostering a robust organizational structure for further expansion.
Hims & Hers Health, Inc. (NYSE: HIMS) announced participation of co-Founder and CEO Andrew Dudum and CFO Yemi Okupe in a fireside chat at Citi’s 2022 Virtual Health Conference on February 24 at 3:30 pm Eastern time. The session will be live-streamed on the Hims & Hers investor relations website, with an archived version available for 12 months. Hims & Hers is a transformative multi-specialty telehealth platform providing access to various healthcare treatments and services.
Hims & Hers Health reported strong Q4 2021 results, with revenues of $84.7 million, up 104% YOY, and full-year revenues of $271.9 million, marking an 83% increase. However, net losses widened to $(31.2) million in Q4 and $(107.7) million for the year. The company ended the year with 609,000 subscriptions, a 95% YOY growth. Looking ahead, guidance for 2022 suggests revenues between $365 million and $380 million but projects Adjusted EBITDA losses between $(30) million and $(20) million.
Hims & Hers Health, Inc. (NYSE: HIMS) announces a new partnership with GNC Holdings to enhance consumer access to health and wellness products. Selected products will be available in GNC stores and online at GNC.com. This collaboration aims to broaden the brand's reach across the U.S., providing consumers with easier access to offerings such as hair care solutions. Hims & Hers now partners with over a dozen retail brands, totaling more than 20,000 locations, reinforcing its mission for mass market accessibility.
Hims & Hers Health (NYSE: HIMS) has launched three new wellness supplements aimed at enhancing mental wellness, targeting issues like stress, sleep disturbances, and lack of focus. The products—Mind Unwind, Double Doze, and Focus Finder—are available via their website and select retailers such as Target and Walgreens. Each supplement incorporates natural ingredients to support consumer wellness journeys, including innovative formulations for prolonged effects.